Search | Clinical Trials Finder

Conditions: Ovarian Cancer, Endometrial Cancer
Interventions: Tc 99m EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer, Urinary Bladder Cancer, Leukemia, Lymphoid Leukemia, Myeloma Multiple, Prostate Cancer, Pancreas Cancer, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Brain Cancer, Melanoma, Mycosis Fungoides, Kidney Cancer
Interventions: Riluzole, Placebo; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Ovarian Cancer
Interventions: ABT-888, pegylated liposomal doxorubicin, temozolomide; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Duarte, California • Encino, California • Los Angeles, California + 12 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
Interventions: SEA-TGT, sasanlimab, brentuximab vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more

Conditions: Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
Interventions: Rucaparib, Lucitanib, Sacituzumab govitecan; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashville, Tennessee • Houston, Texas

Conditions: Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions: PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo); Drug · Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more

Conditions: Frailty at Older Adults, Ovarian Cancer, Endometrial Cancer, Cognitive Dysfunction, Neoadjuvant Chemotherapy
Interventions: data collection; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 55 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 3
States / cities: Ithaca, New York • Rochester, New York

Conditions: Ovarian Cancer
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 31
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Breast Cancer
Interventions: Ovarian stimulation in vitro fertilization cryopreservation; Procedure
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2018
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
Interventions: LY3435151, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: carboplatin, epirubicin hydrochloride, paclitaxel, conventional surgery; Drug · Procedure
Lead sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: PCOS, Polycystic Ovary Syndrome
Interventions: Micronized progesterone, Placebo, Flutamide, Estradiol patch; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma
Interventions: upifitamab rilsodotin; Drug
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Ovarian Cancer
Interventions: Olaparib, Ceralasertib, Placebo to match olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 22
States / cities: Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Ovarian Cancer, Breast Cancer
Interventions: Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 14
States / cities: Boca Raton, Florida • Towson, Maryland • Detroit, Michigan + 11 more

Conditions: Tumors
Interventions: NB1011; Drug
Lead sponsor: Kiadis Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Los Angeles, California • Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1226
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more

Conditions: Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 11 more

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 51
States / cities: Phoenix, Arizona • Burbank, California • Concord, California + 40 more

Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Interventions: Emi-Le; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 26
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 20 more

Conditions: Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions: [18F]FPyQCP; Drug
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

The Better, Harder, Faster, Stronger Study

Nutritional and Metabolic Correlates of Ovarian Morphology in Women With Polycystic Ovary Syndrome

Patient Reported Symptoms in Ovarian Cancer (PRECISION)

Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients

A Study of LY3435151 in Participants With Solid Tumors

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications